Kolektivni imunitet, razvoj vakcine za SARS-COV-2 i pušenje duvana u doba KOVIDA-19
Collective immunity, vaccine development for SARS-COV-2 and tobacco smoking in the age of COVID-19

Summary/Abstract: A new coronavirus, SARS-CoV-2, is responsible for the Covid-19 pandemic. With collective immunity, the threshold is above 50 percent, the chain of virus transmission will be broken. This immunity is acquired in two ways: by the natural spread of the disease and by vaccination. While waiting for the effect of vaccination and acquiring immunity by spreading the disease, the infection can be curbed by epidemiological procedures, and the treatment of Covid-19 is reduced to supportive therapy. Risk factors that aggravate the disease include geriatric age, tobacco smoking, diabetes, arterial hypertension, vascular disease, bronchial asthma, and chronic obstructive pulmonary disease (COPD). Because tobacco smoking leads to a more severe form and higher mortality due to Covid-19, many smokers are motivated to smoke less or quit tobacco during the pandemic. To facilitate smoking cessation, abstinence disorders are alleviated by the pharmaceutical preparations nicotine, bupropion (Zyban) and varenicline (Chantix). The World Health Organization reports that by November 2020, there were more than 164 candidates for the vaccine in the preclinical trial, and 48 vaccines were then clinically evaluated, and today a dozen of them are already in clinical use. In order to acquire the necessary threshold of collective immunity in the world, it may be necessary to produce close to 16 billion doses of vaccine and to organize successful rapid global vaccination. In Serbia, the suppression of Covid-19 can be expected at the latest at the end of 2021 or the beginning of 2022.

• Details
• Contents